SEC Form NT 10-Q filed by bluebird bio Inc.
$BLUE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number: 001-35966
CUSIP Number: 09609G100
(Check One):
☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q
☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
For Period Ended: June 30, 2024
☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q | ||
For the Transition Period Ended:
Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:
PART I-REGISTRANT INFORMATION
| bluebird bio, Inc. | ||
| Full Name of Registrant | ||
| N/A | ||
| Former Name if Applicable | ||
| 455 Grand Union Boulevard | ||
Address of Principal Executive Office (Street and number) | ||
| Somerville, Massachusetts 02145 | ||
| City, State and Zip Code | ||
PART II-RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)
| (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; | |||||||
☐ | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, FORM N-CEN or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and | ||||||
| (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. | |||||||
PART III - NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
bluebird bio, Inc. (the “Company”) has determined that it is unable, without unreasonable effort or expense, to file with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the three months ended June 30, 2024 (the “Second Quarter 2024 Report”) by the prescribed due date for the reasons described below.
As previously reported, the Company is delayed in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”) and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “First Quarter 2024 Report”) due to the need to restate its financial statements for the year ended December 31, 2022 and for each of the first three quarters of 2022 and 2023. As a result of the extended timeline to file the 2023 Form 10-K and the First Quarter 2024 Report, the Company is unable to complete and file the Second Quarter 2024 Report by the required due date of August 14, 2024. The Company continues to work diligently towards completing the restatement and filing the 2023 Form 10-K and the First Quarter 2024 Report as well as the Second Quarter 2024 Report as soon as practicable.
PART IV - OTHER INFORMATION
(1)Name and telephone number of person to contact in regard to this notification.
O. James Sterling | 339 | 499-9300 | ||||||||||||
(Name) | (Area Code) | (Telephone Number) | ||||||||||||
(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
☐ Yes ☒ No
Annual Report on Form 10-K for the year ended December 31, 2023
Quarterly Report on Form 10-Q for the quarter ended March 31, 2024
(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
☒ Yes ☐ No
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
The information set forth in Part III above, as related to the restatement of the financial statements for quarter ended June 30, 2024, is incorporated herein by reference.
The Company anticipates significant changes to its results of operations for the quarter ended June 30, 2024 as compared to the corresponding period ended in 2023. The Company at this time cannot estimate the amount of the changes as it has not fully completed its review.
As previously reported, the identified errors in the periods to be restated resulted from the Company’s identification of leases and the application of its accounting policy for the treatment of non-lease components contained in lease agreements. The Company’s accounting policy required that lease and non-lease components in agreements with contract manufacturing organizations that are accounted for as leases be combined. The Company determined that it did not consistently combine such components. The Company does not expect the errors to result in any impact on its cash position or revenue.
Cautionary Note Regarding Forward-Looking Statements
This Notification of Late Filing on Form 12b-25 (the “Form 12b-25”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 12b-25 that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing of the filing of the Company’s 2023 Form 10-K, First Quarter 2024 Report and Second Quarter 2024 Report and the impact of errors in the Company’s previously-issued financial statements, including on its cash position and revenue. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligations to make any revisions to the forward-looking statements contained in this Form 12b-25 or to update them to reflect events or circumstances occurring after the date of this Form 12b-25, whether as a result of new information, future developments or otherwise.
| bluebird bio, Inc. | ||
| (Name of Registrant as Specified in Charter) | ||
has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
| Date: August 14, 2024 | bluebird bio, Inc. | ||||||||||
| By: | /s/ O. James Sterling | ||||||||||
| O. James Sterling | |||||||||||
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer | |||||||||||